Imlifidase for Kidney Transplantation of Highly Sensitized Patients With a Positive Crossmatch: The French Consensus Guidelines
Transplant International · 2023
DOI: 10.3389/ti.2023.11244 ↗Kurz gefasst
Editorial in der Zeitschrift Transplant International, 2023. Verfasst von Lionel Couzi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. Hauptthemen laut MEDLINE: Kidney Transplantation. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Imlifidase recently received early access authorization for highly sensitized adult kidney transplant candidates with a positive crossmatch against an ABO-compatible deceased donor. These French consensus guidelines have been generated by an expert working group, in order to homogenize patient selection, associated treatments and follow-up. This initiative is part of an international effort to analyze properly the benefits and tolerance of this new costly treatment in real-life. Eligible patients must meet the following screening criteria: cPRA ≥ 98%, ≤ 65-year of age, ≥ 3 years on the waiting list, and a low risk of biopsy-related complications. The final decision to use Imlifidase will be based on the two following criteria. First, the results of a virtual crossmatch on recent serum, which shall show a MFI for the immunodominant donor-specific antibodies (DSA) > 6,000 but the value of which does not exceed 5,000 after 1:10 dilution. Second, the post-Imlifidase complement-dependent cytotoxicity crossmatch must be negative. Patients treated with Imlifidase will receive an immunosuppressive regimen based on steroids, rATG, high dose IVIg, rituximab, tacrolimus and mycophenolic acid. Frequent post-transplant testing for DSA and systematic surveillance kidney biopsies are highly recommended to monitor post-transplant DSA rebound and subclinical rejection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
- CNRS-UMR 5164 Immuno ConcEpT, Université de Bordeaux, Bordeaux, France.
- Centre Hospitalier Universitaire de Grenoble, La Tronche, France.
- Hôpital Necker-Enfants Malades, Paris, France.
- Centre Hospitalier Universitaire (CHU) de Nantes, Nantes, France.
- Hôpital Civil, Strasbourg, Strasbourg, France.
Zitieren
APA
Couzi, L., Malvezzi, P., Amrouche, L., Anglicheau, D., Blancho, G., Caillard, S., Freist, M., Guidicelli, G. L., Kamar, N., Lefaucheur, C., Mariat, C., Koenig, A., Noble, J., Thaunat, O., Thierry, A., Taupin, J. L., & Bertrand, D. (2023). Imlifidase for Kidney Transplantation of Highly Sensitized Patients With a Positive Crossmatch: The French Consensus Guidelines. Transplant International. https://doi.org/10.3389/ti.2023.11244
Vancouver
Couzi L, Malvezzi P, Amrouche L, Anglicheau D, Blancho G, Caillard S, et al. Imlifidase for Kidney Transplantation of Highly Sensitized Patients With a Positive Crossmatch: The French Consensus Guidelines. Transplant International. 2023. doi:10.3389/ti.2023.11244
BibTeX
@article{Couzi2023,
author = {Couzi, Lionel and Malvezzi, Paolo and Amrouche, Lucile and Anglicheau, Dany and Blancho, Gilles and Caillard, Sophie and Freist, Marine and Guidicelli, Gwenda Line and Kamar, Nassim and Lefaucheur, Carmen and Mariat, Christophe and Koenig, Alice and Noble, Johan and Thaunat, Olivier and Thierry, Antoine and Taupin, Jean-Luc and Bertrand, Dominique},
title = {Imlifidase for Kidney Transplantation of Highly Sensitized Patients With a Positive Crossmatch: The French Consensus Guidelines},
journal = {Transplant International},
year = {2023},
doi = {10.3389/ti.2023.11244}
}
EUVIMED